{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:47:51Z","timestamp":1792594071517,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jcf.2023.02.004","type":"journal-article","created":{"date-parts":[[2023,2,26]],"date-time":"2023-02-26T19:20:34Z","timestamp":1677439234000},"page":"607-614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":162,"title":["Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del"],"prefix":"10.1016","volume":"22","author":[{"given":"Andrea","family":"Lopez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Vega-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8455-3424","authenticated-orcid":false,"given":"Gordon","family":"MacGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime L.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2023.02.004_bib0001","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"9678","key":"10.1016\/j.jcf.2023.02.004_bib0002","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O'Sullivan","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jcf.2023.02.004_bib0003","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00018-016-2393-9","article-title":"Cystic fibrosis: a clinical view","volume":"74","author":"Castellani","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jcf.2023.02.004_bib0004","first-page":"64","article-title":"Cystic fibrosis in the era of precision medicine","volume":"25","author":"Paranjape","year":"2018","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.jcf.2023.02.004_bib0005","series-title":"Annual Data Report 2020","year":"2021"},{"issue":"7","key":"10.1016\/j.jcf.2023.02.004_bib0006","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S2213-2600(20)30510-5","article-title":"Long-term safety and efficacy of tezacaftor\u2013ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study","volume":"9","author":"Flume","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2023.02.004_bib0007","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(19)30188-2","article-title":"Real-world outcomes among patients with cystic fibrosis treated with lumacaftor\/ivacaftor (LUM\/IVA) in 2017: an interim analysis of data from the US CF Foundation Patient Registry (CFFPR)","volume":"18","author":"Knox","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2023.02.004_bib0008","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.201503-0578OC","article-title":"Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data","volume":"192","author":"Sawicki","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jcf.2023.02.004_bib0009","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.02.004_bib0010","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.2147\/TCRM.S147164","article-title":"Triplet CFTR modulators: future prospects for treatment of cystic fibrosis","volume":"14","author":"Chaudary","year":"2018","journal-title":"Ther Clin Risk Manag"},{"issue":"19","key":"10.1016\/j.jcf.2023.02.004_bib0011","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcf.2023.02.004_bib0012","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"10212","key":"10.1016\/j.jcf.2023.02.004_bib0013","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2023.02.004_bib0014","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 96-week interim results from an open-label extension study","author":"Daines","year":"2021"},{"key":"10.1016\/j.jcf.2023.02.004_bib0015","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618820186","article-title":"Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor\/ivacaftor","volume":"13","author":"Rubin","year":"2019","journal-title":"Ther Adv Respir Dis"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2023.02.004_bib0016","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.jval.2020.04.044","article-title":"Validation of modeled 5-year survival outcomes among patients with cystic fibrosis (CF) treated with the CF transmembrane conductance regulator modulator (CFTRM) ivacaftor using US CF Foundation Patient Registry (USCFFPR) data","volume":"23","author":"McGarry","year":"2020","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jcf.2023.02.004_bib0017","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/aje\/153.4.345","article-title":"Predictive 5-year survivorship model of cystic fibrosis","volume":"153","author":"Liou","year":"2001","journal-title":"Am J Epidemiol"},{"issue":"21","key":"10.1016\/j.jcf.2023.02.004_bib0018","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2023.02.004_bib0019","series-title":"Annual Data Report 2019","year":"2020"},{"issue":"3","key":"10.1016\/j.jcf.2023.02.004_bib0020","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"10.1016\/j.jcf.2023.02.004_bib0021","first-page":"A222","article-title":"Rate of lung function decline in patients with cystic fibrosis (CF) having a residual function gene mutation","volume":"72","author":"Sawicki","year":"2017","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.jcf.2023.02.004_bib0022","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/thx.2006.060889","article-title":"Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis","volume":"62","author":"Goss","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2023.02.004_bib0023","series-title":"Clinical guidelines: care of children with cystic fibrosis","year":"2020"},{"issue":"1","key":"10.1016\/j.jcf.2023.02.004_bib0024","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1164\/ajrccm.158.1.15812","article-title":"International guidelines for the selection of lung transplant candidates","volume":"158","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2023.02.004_bib0025","series-title":"Slide 26. Adult lung transplants","year":"2017"},{"issue":"10","key":"10.1016\/j.jcf.2023.02.004_bib0026","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1464-5491.2007.02252.x","article-title":"Characteristics of adults with and without cystic fibrosis-related diabetes","volume":"24","author":"Adler","year":"2007","journal-title":"Diabet Med"},{"issue":"6","key":"10.1016\/j.jcf.2023.02.004_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107845","article-title":"Effect of CFTR modulator therapy on cystic fibrosis-related diabetes","volume":"35","author":"Gaines","year":"2021","journal-title":"J Diabetes Complications"},{"issue":"18","key":"10.1016\/j.jcf.2023.02.004_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta18180","article-title":"Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis","volume":"18","author":"Whiting","year":"2014","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jcf.2023.02.004_bib0029","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor (ELX\/TEZ\/IVA) on annual rate of lung function decline in people with cystic fibrosis","author":"Lee","year":"2022"},{"issue":"2","key":"10.1016\/j.jcf.2023.02.004_bib0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.jcf.2023.02.004_bib0031","doi-asserted-by":"crossref","first-page":"0008","DOI":"10.1183\/23120541.00082-2019","article-title":"Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles","volume":"5","author":"Taylor-Cousar","year":"2019","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jcf.2023.02.004_bib0032","series-title":"United Kingdom Total Population","year":"2022"},{"issue":"5","key":"10.1016\/j.jcf.2023.02.004_bib0033","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jcf.2021.05.009","article-title":"Short-term effect of elexacaftor-tezacaftor-ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease","volume":"20","author":"Bermingham","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2023.02.004_bib0034","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor\u2013tezacaftor\u2013ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 2","key":"10.1016\/j.jcf.2023.02.004_bib0035","first-page":"S293","article-title":"Initiation of triple combination CFTR modulator therapy in patients with advanced cystic fibrosis lung disease","volume":"55","author":"Uluer","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.jcf.2023.02.004_bib0036","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jpeds.2006.04.059","article-title":"Potential impact of newborn screening for cystic fibrosis on child survival: a systematic review and analysis","volume":"149","author":"Grosse","year":"2006","journal-title":"J Pediatr"},{"issue":"Suppl3","key":"10.1016\/j.jcf.2023.02.004_bib0037","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jpeds.2005.08.009","article-title":"Review of outcomes of neonatal screening for cystic fibrosis versus non-screening in Europe","volume":"147","author":"Dankert-Roelse","year":"2005","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.jcf.2023.02.004_bib0038","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jcf.2015.09.008","article-title":"Cystic fibrosis in young children: a review of disease manifestation, progression, and response to early treatment","volume":"15","author":"VanDevanter","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2023.02.004_bib0039","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jcf.2020.07.017","article-title":"Projecting the impact of delayed access to elexacaftor\/tezacaftor\/ivacaftor for people with cystic fibrosis","volume":"20","author":"Stanojevic","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.02.004_bib0040","first-page":"1","article-title":"Mortality trends by race and ethnicity among adults aged 25 and over: United States, 2000\u20132017","volume":"342","author":"Curtin","year":"2019","journal-title":"NCHS Data Brief"},{"issue":"3","key":"10.1016\/j.jcf.2023.02.004_bib0041","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.gastro.2017.12.012","article-title":"Cystic fibrosis colorectal cancer screening consensus recommendations","volume":"154","author":"Hadjiliadis","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcf.2023.02.004_bib0042","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejogrb.2017.12.005","article-title":"High proportion of abnormal pap smear tests and cervical dysplasia in women with cystic fibrosis","volume":"221","author":"Rousset-Jablonski","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"3","key":"10.1016\/j.jcf.2023.02.004_bib0043","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s44161-022-00030-y","article-title":"Identifying and preventing cardiovascular disease in patients with cystic fibrosis","volume":"1","author":"Saunders","year":"2022","journal-title":"Nat Cardiovasc Res"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T22:33:23Z","timestamp":1751582003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323000486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1569199323000486"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.02.004","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}